Trump Says Anthropic No Longer Seen as National Security Threat 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
WALTHAM, Mass., Feb. 04, 2016 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2015 before the U.S. financial markets open on Wednesday, February 17, 2016. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will present an update on recent developments and discuss the company’s fourth quarter and full year 2015 financial and operating results.
To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on February 17, 2016 through midnight on February 24, 2016. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 44838187.
The call will be webcast with slides and accessible through the Investors section of the company’s website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on February 17, 2016 through midnight on March 18, 2016.
About AMAG
AMAG Pharmaceuticals uses its business and clinical expertise to develop and commercialize products that provide clear benefits and improve people’s lives. Based in Waltham, MA, AMAG has a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care. AMAG continues to work to expand the impact of these and future products for patients by delivering on its growth strategy, which includes organic growth, as well as the pursuit of products and companies that align with AMAG’s existing therapeutic areas or those that could benefit from its proven core competencies. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals Contact: Maryann Cimino Manager, Corporate Communications & External Affairs 617-498-3375
